Research
Prediction of Human Pharmacokinetic Profiles of Glyph Platform Prodrugs Using Animal and Human Data via a Semi-mechanistic Pharmacokinetic Model
GlyphAllo, a Novel, Orally Bioavailable Prodrug of Allopregnanolone, Induces an EEG Profile Consistent with GABAA Positive Allosteric Modulation in Healthy Volunteers
Predicted Liver Safety of GlyphAgo, a Lymphatic-targeting Prodrug of Agomelatine That Avoids First-pass Metabolism
Frequency of Rater-based Efficacy Assessments Correlated with Magnitude of Placebo Response in Generalized Anxiety Disorder Trials
GlyphCBD (SPT-310), a Lymphatic-Targeting Prodrug of Cannabidiol, Significantly Inhibits Seizure Activity in the Maximal Electroshock Seizure Model
SPT-320, a First-in-Class Prodrug of Agomelatine that Avoids
First-Pass Hepatic Metabolism via Lymphatic System Absorption
Clinician-administered assessments and impact on placebo response in recent major depressive disorder (MDD) clinical trials
First-in-human Translation of a Biomimetic Glyceride Prodrug Platform: Enabling Avoidance of First-pass Metabolism via Lymphatic Absorption
SPT-300, a First-in-Class Orally Bioavailable Prodrug of the Neurosteroid Allopregnanolone: Safety, Tolerability, and Clinical Pharmacology in Healthy Volunteers
